EGFRvIII Promotes the Proneural–Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-κB/ALDH1A3 Axis

Shi, Zhongcheng; Li, Guanzhang; Zhai, You; Pan, Changqing; Wang, Di; Yu, Mingchen; Liu, Chi; Zhang, Wei; Yu, Xiaoguang

doi:10.3390/genes14030651

Cited by 9 publications

(2 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SOAT1 inhibitor avasimibe can prevent the formation of cerebral gliomas in xenograft model mice and extend animal longevity [54]. Moreover, avasimibe limits the viability of the GBM cell line, EGFRvIII U87, without damaging astrocytes [54][55][56]. Moreover, avasimibe prevents the development of GBM cells by inducing cell cycle arrest and activating caspase-8-dependent apoptotic pathways [54].…”

Section: Cholesterol Can Get In the Cells Through Low-density Lipopro...mentioning

confidence: 99%

The effects of statin therapy on brain tumors, particularly glioma: a review

Alrosan,

Heilat,

Al Subeh

et al. 2023

Anti-Cancer Drugs

View full text Add to dashboard Cite

Brain tumors account for less than 2% of all malignancies. However, they are associated with the highest morbidity and mortality rates among all solid tumors. The most common malignant primary brain tumors are glioma or glioblastoma (GBM), which have a median survival time of about 14 months, often suffer from recurrence after a few months following treatment, and pose a therapeutic challenge. Despite recent therapeutic advances, the prognosis for glioma patients is poor when treated with modern therapies, including chemotherapy, surgery, radiation, or a combination of these. Therefore, discovering a new target to treat brain tumors, particularly glioma, might be advantageous in raising progression-free survival and overall survival (OS) rates. Statins, also known as competitive HMG-CoA reductase inhibitors, are effective medications for reducing cholesterol and cardiovascular risk. The use of statins prior to and during other cancer treatments appears to enhance patient outcomes according to preclinical studies. After surgical resection followed by concurrent radiation and treatment, OS for patients with GBM is only about a year. Statins have recently emerged as potential adjuvant medications for treating GBM due to their ability to inhibit cell growth, survival, migration, metastasis, inflammation, angiogenesis, and increase apoptosis in-vitro and in-vivo studies. Whether statins enhance clinical outcomes, such as patient survival in GBM, is still debatable. This study aimed to explore the effects of statin therapy in the context of cancer treatment, with a particular focus on GBM.

show abstract

Section: Cholesterol Can Get In the Cells Through Low-density Lipopro...mentioning

confidence: 99%

The effects of statin therapy on brain tumors, particularly glioma: a review

Alrosan,

Heilat,

Al Subeh

et al. 2023

Anti-Cancer Drugs

View full text Add to dashboard Cite

show abstract

“…Mucin1 (MUC1), by regulated NF-κB signal transcription, can promote GBM progression and TMZ resistance by stabilizing EGFRvIII [ 123 ]. Additionally, the EGFRvIII activation NF-κB pathway further regulates the expression of ALDH1A3, promoting the anterior neural mesenchymal transformation of GBM, thus reducing its sensitivity to TMZ [ 124 ].…”

Section: Nf-κb Activation Is Involved In Development and Progression ...mentioning

confidence: 99%

The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma

Shi

Cui

2023

IJMS

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common and invasive primary central nervous system tumor in humans, accounting for approximately 45–50% of all primary brain tumors. How to conduct early diagnosis, targeted intervention, and prognostic evaluation of GBM, in order to improve the survival rate of glioblastoma patients, has always been an urgent clinical problem to be solved. Therefore, a deeper understanding of the molecular mechanisms underlying the occurrence and development of GBM is also needed. Like many other cancers, NF-κB signaling plays a crucial role in tumor growth and therapeutic resistance in GBM. However, the molecular mechanism underlying the high activity of NF-κB in GBM remains to be elucidated. This review aims to identify and summarize the NF-κB signaling involved in the recent pathogenesis of GBM, as well as basic therapy for GBM via NF-κB signaling.

show abstract

The multifaceted therapeutical role of low‐density lipoprotein receptor family in high‐grade glioma

Mastrantuono,

Ghibaudi,

Matias

et al. 2024

Molecular Oncology

View full text Add to dashboard Cite

The diverse roles of the low‐density lipoprotein receptor family (LDLR) have been associated with many processes critical to maintaining central nervous system (CNS) health and contributing to neurological diseases or cancer. In this review, we provide a comprehensive understanding of the LDLR's involvement in common brain tumors, specifically high‐grade gliomas, emphasizing the receptors' critical role in the pathophysiology and progression of these tumors due to LDLR's high expression. We delve into LDLR's role in regulating cellular uptake and transport through the brain barrier. Additionally, we highlight LDLR's role in activating several signaling pathways related to tumor proliferation, migration, and invasion, engaging readers with an in‐depth understanding of the molecular mechanisms at play. By synthesizing current research findings, this review underscores the significance of LDLR during tumorigenesis and explores its potential as a therapeutic target for high‐grade gliomas. The collective insights presented here contribute to a deeper appreciation of LDLR's multifaceted roles and implications for physiological and pathological states, opening new avenues for tumor treatment.

show abstract

EGFRvIII Promotes the Proneural–Mesenchymal Transition of Glioblastoma Multiforme and Reduces Its Sensitivity to Temozolomide by Regulating the NF-κB/ALDH1A3 Axis

Cited by 9 publications

References 66 publications

The effects of statin therapy on brain tumors, particularly glioma: a review

The effects of statin therapy on brain tumors, particularly glioma: a review

The Recent Research Progress of NF-κB Signaling on the Proliferation, Migration, Invasion, Immune Escape and Drug Resistance of Glioblastoma

The multifaceted therapeutical role of low‐density lipoprotein receptor family in high‐grade glioma

Contact Info

Product

Resources

About